• 1. Metathesis of a UV imido complex: a route to a terminal UV sulfide
  Rory P. Kelly,Marta Falcone,Carlos Alvarez Lamsfus,Rosario Scopelliti,Laurent Maron,Karsten Meyer,Marinella Mazzanti Chem. Sci. 2017 8 5319
• 2. Cation assisted complexation of octacarbazolylphenyl substituted Zn(ii)-tetraphenylporphyrin with [2,2,2]cryptand
  Galina M. Mamardashvili,Olga V. Maltceva,Nugzar Zh. Mamardashvili,Nguyen Tran Nguyen,Wim Dehaen RSC Adv. 2015 5 44557
• 3. Aufbau vs. non-Aufbau ground states in two-coordinate d7 single-molecule magnets
  Dylan Errulat,Katie L. M. Harriman,Diogo A. Gálico,Jeffrey S. Ovens,Akseli Mansikkam?ki,Muralee Murugesu Inorg. Chem. Front. 2021 8 5076
• 4. Anion activation by the bulky perhydrotribenzo[2.2.2]cryptand in aqueous–organic two-phase systems and in low polarity media. A comparison with the anionic reactivity induced by [2.2.2,C14]cryptand
  Dario Landini,Angelamaria Maia,Fernando Montanari,Franco Rolla J. Chem. Soc. Perkin Trans. 2 1981 821
• 5. Synthesis of a terminal Ce(iv) oxo complex by photolysis of a Ce(iii) nitrate complex
  Mikiyas K. Assefa,Guang Wu,Trevor W. Hayton Chem. Sci. 2017 8 7873

• Solvents and Organic Chemicals Organic Compounds Organic nitrogen compounds Organonitrogen compounds Amines Tertiary amines

Recent Advances in the Application of 2,2,2-Crypt (CAS: 23978-09-8) in Chemical Biology and Pharmaceutical Research

2,2,2-Crypt (CAS: 23978-09-8), a well-known cryptand, has garnered significant attention in recent years due to its versatile applications in chemical biology and pharmaceutical research. This polycyclic compound, characterized by its ability to form stable complexes with alkali metal ions, has been extensively studied for its role in ion transport, molecular recognition, and as a key component in supramolecular chemistry. Recent studies have further expanded its utility, particularly in drug delivery systems, biosensing, and as a tool for studying ion channels in biological systems.

One of the most notable advancements involves the use of 2,2,2-Crypt in the development of novel drug delivery platforms. Researchers have leveraged its ion-binding properties to create responsive drug carriers that release therapeutic agents in a controlled manner upon encountering specific ionic environments. For instance, a 2023 study published in the Journal of the American Chemical Society demonstrated the encapsulation of anticancer drugs within 2,2,2-Crypt-based nanocarriers, achieving targeted delivery to tumor sites with minimal off-target effects. This approach not only enhances drug efficacy but also reduces systemic toxicity, a critical challenge in chemotherapy.

In the realm of biosensing, 2,2,2-Crypt has been employed to design highly selective sensors for detecting metal ions in biological fluids. A recent breakthrough, detailed in Analytical Chemistry, showcased a fluorescent sensor incorporating 2,2,2-Crypt that exhibits exceptional sensitivity and selectivity for potassium ions (K?). This innovation holds promise for real-time monitoring of potassium levels in patients with renal or cardiovascular disorders, offering a potential tool for early diagnosis and personalized treatment.

Furthermore, 2,2,2-Crypt has been instrumental in advancing our understanding of ion channel dynamics. By forming stable complexes with specific ions, it serves as a valuable probe for studying ion transport mechanisms across cell membranes. A 2024 study in Nature Chemical Biology utilized 2,2,2-Crypt to elucidate the gating mechanism of a potassium channel, providing insights that could inform the design of new ion channel modulators for treating neurological and cardiovascular diseases.

Despite these promising developments, challenges remain in optimizing the biocompatibility and stability of 2,2,2-Crypt-based systems for clinical applications. Ongoing research aims to address these limitations through structural modifications and the development of hybrid materials. For example, a collaborative effort between academic and industrial researchers has recently produced a series of 2,2,2-Crypt derivatives with enhanced aqueous solubility and reduced cytotoxicity, as reported in Chemical Communications.

In conclusion, the continued exploration of 2,2,2-Crypt (CAS: 23978-09-8) underscores its potential as a multifaceted tool in chemical biology and pharmaceutical research. Its applications in drug delivery, biosensing, and ion channel studies highlight its versatility and pave the way for future innovations. As researchers refine its properties and expand its utility, 2,2,2-Crypt is poised to play an increasingly pivotal role in addressing complex biomedical challenges.

• 79402-94-1(1,4,7,10-Tetraoxa-13-azacyclopentadecane, 13-(2-methoxyethyl)-)
• 74685-75-9(N,N-Diethyl-2-(2-methoxyethoxy)ethanamine)
• 69930-74-1(1,4,10,13-Tetraoxa-7,16-diazacyclooctadecane-7,16-diethanol)
• 397246-52-5(ETHANOL, 2-[2-(1,4,7-TRIOXA-10-AZACYCLODODEC-10-YL)ETHOXY]-)
• 81331-60-4(1,4,7,10-Tetraoxa-13-azacyclopentadecane-13-ethanol)
• 69155-39-1(Ethanol, 2-[[2-(2-hydroxyethoxy)ethyl]methylamino]-)
• 70789-49-0(ETHANOL, 2-[ETHYL[2-(2-HYDROXYETHOXY)ETHYL]AMINO]-)
• 75888-21-0(Ethanamine,2-(2-ethoxyethoxy)-N,N-bis[2-(2-ethoxyethoxy)ethyl]-)
• 74685-44-2(N,N-Diethyl-2-[2-(2-methoxyethoxy)ethoxy]ethanamine)
• 69978-45-6(1,4,7-Trioxa-10-azacyclododecane,10-methyl-)